Contraception and post abortion services: qualitative analysis of users' perspectives and experiences following Zika epidemic in Honduras.


Journal

BMC women's health
ISSN: 1472-6874
Titre abrégé: BMC Womens Health
Pays: England
ID NLM: 101088690

Informations de publication

Date de publication:
12 09 2020
Historique:
received: 17 12 2019
accepted: 01 09 2020
entrez: 13 9 2020
pubmed: 14 9 2020
medline: 12 2 2021
Statut: epublish

Résumé

Zika virus (ZIKV) infection during pregnancy has severe consequences on the new-born. The World Health Organization declared the Zika outbreak to be a Public Health Emergency of International Concern (PHEIC) in 2016. Health facilities in the regions most affected by Zika lacked the capacity to respond to the increased demand for contraception. The objectives were to explore healthcare users' perceptions regarding contraception, Zika prevention during pregnancy and post-abortion care (PAC) services in the context of a Zika outbreak in Tegucigalpa, Honduras, and to follow these services over time. This study was part of a broader implementation research study. We used qualitative research consistent with grounded theory approach. Semi-structured interviews and focus groups were performed with women and their partners who used contraceptive services or received PAC services. Data were collected in two stages from December 2017 to July 2018. Themes explored included contraception, Zika and PAC services. Participants had positive attitude towards the use of contraceptive methods and demanded more information on safety, efficacy and on side effects. Health care services were inconsistent in the provision of information on Zika and contraception services. ZIKV vector transmission was known but fewer participants were aware of risk of sexual transmission of Zika. Barriers to access healthcare services included contraceptive and PAC services included distance to healthcare facilities, disorganized admission process, long waiting times and out-of-pocket expenditure to purchase medicines. Furthermore, poor quality, mistreatment and abuse of women seeking PAC was prevalent. Some positive changes were noted over time, such as improvements in infrastructure including improved privacy and cleanliness, removal of fees, requisite to bring clean water to hospital. Our results highlight the challenges and areas for improvement in policy and practice related to contraceptive services and PAC in the context of ZIKV infection. Public policies to prevent epidemics should focus more on providing proper sanitation; removing barriers to access and use of effective contraception as human rights priority. Zika epidemic has highlighted weaknesses in health systems that obstruct access to and use of sexual and reproductive health services. The study results call for increased efforts to improve access, especially for women of low socio-economic status and intervene at different levels to eradicate discrimination and improve equity in the provision of health care. Qualitative methods can capture the community perspectives and can provide useful information to develop interventions to improve services.

Sections du résumé

BACKGROUND
Zika virus (ZIKV) infection during pregnancy has severe consequences on the new-born. The World Health Organization declared the Zika outbreak to be a Public Health Emergency of International Concern (PHEIC) in 2016. Health facilities in the regions most affected by Zika lacked the capacity to respond to the increased demand for contraception. The objectives were to explore healthcare users' perceptions regarding contraception, Zika prevention during pregnancy and post-abortion care (PAC) services in the context of a Zika outbreak in Tegucigalpa, Honduras, and to follow these services over time.
METHODS
This study was part of a broader implementation research study. We used qualitative research consistent with grounded theory approach. Semi-structured interviews and focus groups were performed with women and their partners who used contraceptive services or received PAC services. Data were collected in two stages from December 2017 to July 2018. Themes explored included contraception, Zika and PAC services.
RESULTS
Participants had positive attitude towards the use of contraceptive methods and demanded more information on safety, efficacy and on side effects. Health care services were inconsistent in the provision of information on Zika and contraception services. ZIKV vector transmission was known but fewer participants were aware of risk of sexual transmission of Zika. Barriers to access healthcare services included contraceptive and PAC services included distance to healthcare facilities, disorganized admission process, long waiting times and out-of-pocket expenditure to purchase medicines. Furthermore, poor quality, mistreatment and abuse of women seeking PAC was prevalent. Some positive changes were noted over time, such as improvements in infrastructure including improved privacy and cleanliness, removal of fees, requisite to bring clean water to hospital.
CONCLUSIONS
Our results highlight the challenges and areas for improvement in policy and practice related to contraceptive services and PAC in the context of ZIKV infection. Public policies to prevent epidemics should focus more on providing proper sanitation; removing barriers to access and use of effective contraception as human rights priority. Zika epidemic has highlighted weaknesses in health systems that obstruct access to and use of sexual and reproductive health services. The study results call for increased efforts to improve access, especially for women of low socio-economic status and intervene at different levels to eradicate discrimination and improve equity in the provision of health care. Qualitative methods can capture the community perspectives and can provide useful information to develop interventions to improve services.

Identifiants

pubmed: 32919474
doi: 10.1186/s12905-020-01066-7
pii: 10.1186/s12905-020-01066-7
pmc: PMC7488691
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

199

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Large Anonymous Donor under the Grant ID 5149 for Women, Communities, and Health Systems in the Context of Zika.
ID : 5149

Références

Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
Hum Resour Health. 2016 Mar 12;14:10
pubmed: 26971317
N Engl J Med. 2019 Aug 8;381(6):497-499
pubmed: 31216418
Cad Saude Publica. 2016 May;32(5):e00046316
pubmed: 27192024
Reprod Health. 2017 Feb 2;14(1):18
pubmed: 28153043
Reprod Health Matters. 2012 Dec;20(40):94-101
pubmed: 23245414
N Engl J Med. 2019 Oct 10;381(15):1444-1457
pubmed: 31597021
Am J Bioeth. 2016 May;16(5):1-4
pubmed: 27111356
Int J Gynaecol Obstet. 2020 Jan;148 Suppl 2:29-35
pubmed: 31975397
PLoS One. 2018 Jan 3;13(1):e0190024
pubmed: 29298358
Eur J Obstet Gynecol Reprod Biol. 2018 Sep;228:255-260
pubmed: 30041146
PLoS Curr. 2016 Mar 16;8:
pubmed: 28515967
Obstet Gynecol. 2017 Apr;129(4):638-642
pubmed: 28277362
Glob Public Health. 2014;9(4):455-68
pubmed: 24593192
Curr Opin Obstet Gynecol. 2016 Dec;28(6):499-503
pubmed: 27787288
Cien Saude Colet. 2017 Aug;22(8):2771-2780
pubmed: 28793091
BMC Health Serv Res. 2018 Nov 29;18(1):909
pubmed: 30497464
Semin Reprod Med. 2016 Sep;34(5):305-312
pubmed: 27612157
Soc Sci Med. 2005 Mar;60(6):1175-85
pubmed: 15626515
N Engl J Med. 2016 Apr 21;374(16):1552-63
pubmed: 27028561
MMWR Morb Mortal Wkly Rep. 2017 Jan 06;65(52):1482-1488
pubmed: 28056005
Reprod Health. 2009 Nov 19;6:19
pubmed: 19925660
Contraception. 2019 Aug;100(2):137-141
pubmed: 30980825
Eur J Contracept Reprod Health Care. 2016 Jun;21(3):213-9
pubmed: 26848851
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
Contraception. 2017 Jun;95(6):549-557
pubmed: 28126542
BMJ Glob Health. 2019 Mar 7;4(2):e001257
pubmed: 30997169
Reprod Health Matters. 2016 Nov;24(48):57-61
pubmed: 28024678

Auteurs

Maria Belizan (M)

Mother and Child Health Research Department, Qualitative Health Research Unit, Institute for Clinical Effectiveness and Health Policy - IECS, Buenos Aires, Argentina.

Edna Maradiaga (E)

Instituto de Enfermedades Infecciosas y Parasitología Antonio Vidal, Unidad de Investigación Científica, Facultad de Ciencias Médicas UNAH, Tegucigalpa, Honduras.

Javier Roberti (J)

Mother and Child Health Research Department, Qualitative Health Research Unit, Institute for Clinical Effectiveness and Health Policy - IECS, Buenos Aires, Argentina.

Maricela Casco-Aguilar (M)

Instituto de Enfermedades Infecciosas y Parasitología Antonio Vidal, Unidad de Investigación Científica, Facultad de Ciencias Médicas UNAH, Tegucigalpa, Honduras.

Alison F Ortez (AF)

Instituto de Enfermedades Infecciosas y Parasitología Antonio Vidal, Unidad de Investigación Científica, Facultad de Ciencias Médicas UNAH, Tegucigalpa, Honduras.

Juan C Avila-Flores (JC)

Instituto de Enfermedades Infecciosas y Parasitología Antonio Vidal, Unidad de Investigación Científica, Facultad de Ciencias Médicas UNAH, Tegucigalpa, Honduras.

Gloria González (G)

Department of Obstetrics and Gynecology, Hospital Escuela, Tegucigalpa, Honduras.

Carolina Bustillo (C)

Department of Obstetrics and Gynecology, Hospital Escuela, Tegucigalpa, Honduras.

Alejandra Calderón (A)

Centro de Salud Alonso Suazo, Región Metropolitana del Distrito Central, Tegucigalpa, Honduras.

Harry Bock (H)

Harry Bock. Región Metropolitana del Distrito Central, Tegucigalpa, Honduras.

María L Cafferata (ML)

Mother and Child Health Research Department, Qualitative Health Research Unit, Institute for Clinical Effectiveness and Health Policy - IECS, Buenos Aires, Argentina.

Adriano B Tavares (AB)

Department of Reproductive Health and Research, World Health Organization, Avenue Appia 20, CH-1211, Geneva 27, Switzerland.

Jackeline Alger (J)

Instituto de Enfermedades Infecciosas y Parasitología Antonio Vidal, Unidad de Investigación Científica, Facultad de Ciencias Médicas UNAH, Tegucigalpa, Honduras.

Moazzam Ali (M)

Department of Reproductive Health and Research, World Health Organization, Avenue Appia 20, CH-1211, Geneva 27, Switzerland. alimoa@who.int.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH